Immnunohistochemical expression of epidermal growth factor and its prognostic value for gastrointestinal stromal tumors;Determinación inmunohistoquímica y utilidad pronóstica del receptor del factor de crecimiento epidérmico en los tumores estromales gastrointestinales

Revista Espanola de Enfermedades Digestivas

Volumn 100, Issue 12, 2008, Pages 752-757

  Padilla Valverde, David ^a   Menendez P ^a   Garcia M ^a   Villarejo, P ^a   Cubo, T ^a   Gambi D ^a   Pardo, R ^a   Martin J ^a  

^a Hospital General   (Spain)

Author keywords

EGFR; Gastrointestinal stromal tumors; Prognosis

Indexed keywords

CD34 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; KI 67 ANTIGEN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P53; PROTEIN S 100; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR RECEPTOR; VIMENTIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CELL TYPE; CLINICAL FEATURE; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; EPITHELIOID CELL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOLOGY; HOSPITAL DEPARTMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MITOSIS INDEX; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEX; SPINDLE CELL; STOMACH; TUMOR NECROSIS; AGED; BIOSYNTHESIS; CHEMISTRY; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 64749097983     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Damjanov I. Small intestine. En: Damjanov I, Linder J, editors. Anderson's Pathology.10th ed. St. Louis: Mosby-Year Book Inc; 1996. p. 1708-1727
2. Pike AM, Lloyd RV, Appelman HD. Cell markers in gastrointestinal stromal tumors. Human Pathology 1998; 19: 830-834
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Review on morphology, molecular pathology, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-1478
4. Fletcher C, Berman J, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors. A consensus approach. Hum Pathol 2002; 33: 459-465
5. Poveda A, Maurel J, Martín J, Artigas V, Casado A, Cervera J, et al. Guía de práctica clínica en los tumores estromales gastrointestinales. Cir Esp 2005; 78: 1-13.
6. Fletcher C, Berman J, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consencus approach. In J Surg Pathol 2002; 10: 81-89 (Pubitemid 34655094)
7. Suster S. Gastrointestinal stromal tumors. Seminars in diagnostic pathology 1996; 13: 297-313. (Pubitemid 26399397)
8. Lopes LF, Bacchi CL. EGFR and gastrointestinal stromal tumor: an immunohistochemical and Fish study of 82 cases. Modern Pathology 2007; 20: 990-994 (Pubitemid 47267827)
9. Lopes LF, Ojopi LB, Bacchi CE. Gastrointestinal stromal tumor in Brazil: clinicopathology, immunohistochemistry, and molecular genetics of 513 cases. Pathol Int 2008; 58: 344-352
10. Cai YC, Jiang Z, Vittimberga F, Xu X, Savas L, Woda B, et al. Expression of transforming growth factor and epidermal growth factor receptor in gastrointestinal stromal tumours. Virchows Arch 1999; 435; 112-115
11. Lanzafame S, Minutolo V, Caltabiano R, Munutolo O, Marino B, Gangliano G, et al. About a case of GIST ocurring during pregnancy with immunohistochemical expresion of epidermal growth factor receptor and progesterona receptor. Pathology 2006; 202: 119-123
12. Wang X, Zhang S, MacLennan GT, Eble JN, Lopez-Beltran A, Yang X, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 2007; 13: 953-957
13. Sanchez Hidalgo JM, Muñoz Casares FC, Rufián Peña S, Naranjo Torres A, Ciria Bru R, Briceño Delgado J, et al. Tumores del estroma gastrointestinal (GIST): factores pronósticos de supervivencia tras citorreducción R0. Rev Esp Enferm Dig 2007; 99: 703-708
14. Fernández Salazar LI, Alvárez Gago T, Sanz Rubiales A, Velayos Jiménez B, Aller de la Fuente R, González Hernández JM. Tumores del estroma gastrointestinal (GIST): aspectos clínicos. Rev Esp Enferm Dig 2007; 99: 19-24.
15. Pardo Martínez C, Mayol Martínez J, Hernández Pérez C, Álvarez Fernández-Represa J. Gastric stromal tumors: clinical presentation and surgical options. Rev Esp Enferm Dig 2004; 96: 578-583 (Pubitemid 39378311)
16. Fernández A, Aparicio J. Imatinib y tumor del estroma gastrointestinal (GIST): un tratamiento selectivo frente a una diana molecualar. Rev Esp Enferm Dig 2004; 96: 723-729
17. Shchmelinin I, Sefc L, Necas E. Protein kinase inhibitors. Folia Biologica (Praha) 2006; 52: 137-148 (Pubitemid 44613138)
18. Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Molecular cancer therapeutics 2003; 2: 699-709.
19. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Debaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patines with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113 (Pubitemid 46596763)
20. Samelis GF, Ekmektzzoglou KA, Zografos GC. Gastrointestinal stromal tumours: clinical overwiew, surgery and recent advances in imatinib mesylate therapy. EJSO 2007; 33: 942-950 (Pubitemid 47421560)
21. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63: 513-522 (Pubitemid 36337730)
22. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacology and Therapeutics 2004; 102: 37-46. (Pubitemid 38429984)
23. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocrine-Related Cancer 2004; 11: 689-708. (Pubitemid 40065545)
24. Baselga J, Arteaga CL. Clinical update and emerging trends in epidermal growth factor receptor targeting in cancer. J C Oncol 2005; 23: 2445-2459 (Pubitemid 47050835)
25. Normanno N, Gullick WJ. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocrine-Related cancer 2006; 13: 3-6.
26. Ciardello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endotelial growth factor (VEGF) pathways: a rational approach for multi-targetanticancer therapy. Ann Oncol 2006; 17: 109-114